ASH 2020 | Bispecific antibodies for myeloma: highlights from ASH 2020
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, provides an overview of the latest data announced at ASH 2020 on both new and previously reported B-cell maturation antigen (BCMA)-targeting bispecific antibodies for multiple myeloma therapy. The promising data on bispecifics targeting BCMA could cause experts to re-evaluate the need for chimeric antigen receptor (CAR) T-cell therapies. He also highlights GPRC5D and FcRH5, two novel bispecific targets presented at ASH 2020, which show great promise for the treatment of myeloma in the future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
